Results 91 to 100 of about 21,018 (198)
Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B‐cell lymphoma cohort
British Journal of Haematology, Volume 208, Issue 1, Page 139-148, January 2026.The international prognostic index (IPI)‐driven trial inclusion criteria may have contributed to the failure of some of the first‐line trials in large B‐cell lymphoma (LBCL). GLA and LYSA collaborated to improve prognostic stratification in LBCL by analyzing data from trial cohorts and proposed the smIPI.Umut Yılmaz, Esra Terzi Demirsoy, Fatma Keklik Karadağ, Uğur Hatipoğlu, Meral Uluköylü Mengüç, Ebru Pekgüç, Taner Tan, Eda Nuhoğlu Kantarcı, Metban Mastanzade, Ali Durdu, Merve Apaydın Kayer, Murat Özbalak, Tuğrul Elverdi, Asu Fergün Yılmaz, Deniz Gören, Tayfur Toptaş, Turgay Ulaş, Özgür Mehtap, Mehmet Sinan Dal, Olga Meltem Akay, Muhlis Cem Ar, Güray Saydam, Fevzi Altuntaş, Elif Birtaş Ateşoğlu, Burhan Ferhanoğlu +24 morewiley +1 more sourceEffect of CYP3A perpetrators on ibrutinib exposure in healthy participants [PDF]
, 2015 Jan de Jong, Donna Skee, Joe Murphy, Juthamas Sukbuntherng, Peter Hellemans, Johan W. Smit, Ronald de Vries, Juhui James Jiao, Jan Snoeys, Erik Mannaert +9 moreopenalex +1 more sourcePortuguese real-world experience with ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma
Frontiers in HematologyBackgroundMantle cell lymphoma is usually characterized by an aggressive and recurrent course. Clinical trials and real-world series have demonstrated clinical benefits with the use of ibrutinib as a second-line treatment, compared to later relapses ...Catarina Fernandes, Rita Costa e Sousa, Pedro Santos, Cátia Almeida, Adriana Roque, Ana Luísa Pinto, Joaquim Monteiro, Anabela Neves, Maria João Ramos, Rita Coutinho, Rita Coutinho, Rita Coutinho, Filipa Mousinho, Mariana Leal Fernandes, Margarida Badior, Cristina João, Cristina João, Sónia Leocádio, Ana Luísa Tomé, Margarida Carrolo, Sara Dias, Maria Gomes da Silva, João Paulo Fernandes +22 moredoaj +1 more sourceIbrutinib Promotes Atrial Fibrillation by Disrupting A-Kinase Anchoring Protein 1-Mediated Mitochondrial Quality Surveillance in Cardiomyocytes
ResearchBackground: Ibrutinib, a potent Bruton’s tyrosine kinase inhibitor with marked efficacy against hematological malignancies, is associated with the heightened risk of atrial fibrillation (AF).Yukun Li, Xinmeng Liu, Rong Lin, Xiaodong Peng, Xuesi Wang, Fanchao Meng, Shuqi Jin, Wenhe Lv, Xiaoying Liu, Zhuohang Du, Songnan Wen, Rong Bai, Yanfei Ruan, Hao Zhou, Rongjun Zou, Ribo Tang, Nian Liu +16 moredoaj +1 more sourcePhase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia [PDF]
, 2018 Kerry A. Rogers, Ying Huang, Amy S. Ruppert, Farrukh T. Awan, Nyla A. Heerema, Corinne Hoffman, Gerard Lozanski, Kami J. Maddocks, Mollie E. Moran, Mark A. Reid, Margaret S. Lucas, Jennifer A. Woyach, W. Thomas Whitlow, Jeffrey A. Jones, John C. Byrd +14 moreopenalex +1 more sourceCAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) [PDF]
, 2021 Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Ryan Jacobs, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jackson, Bryone J. Kuss, Carol Moreno, E. Szafer-Glusman, Kristin Russell, Cathy Zhou, Joi Ninomoto, James P. Dean, Paolo Ghia, William G. Wierda +19 moreopenalex +1 more sourceIbrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy
, 2014 Fabio Da Roit, Patrick Engelberts, Ronald P. Taylor, Esther C.W. Breij, Giuseppe Gritti, Alessandro Rambaldi, Martino Introna, Paul W.H.I. Parren, Frank J. Beurskens, Josée Golay +9 moreopenalex +2 more sources
